Clinical Trial Update: Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib in combination with 5-azacitidine as initial therapy for AML and high-risk MDS with FLT3-ITD mutation; trial completed with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• 5-Azacitidine (azacitidine)
• Sorafenib (Sorafenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2020-01-06